Amundi Takes $427.62 Million Position in Abbott Laboratories (NYSE:ABT)

Monday, 25 October 2021, 18:50:43
Amundi bought a new stake in shares of Abbott Laboratories (NYSE:ABT) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 3,688,607 shares of the healthcare product makers stock, valued at approximately $427,622,000. Amundi owned 0.21% of Abbott Laboratories as of its most recent []
— Dakota Financial News

Abbott Laboratories (NYSE:ABT) Stock Position Lowered by Fairview Capital Investment Management LLC

Monday, 25 October 2021, 15:38:41
Fairview Capital Investment Management LLC lowered its position in shares of Abbott Laboratories (NYSE:ABT) by 3.6% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,615 shares of the healthcare product makers stock after selling 207 shares during the quarter. Fairview Capital Investment Management []
— Dakota Financial News

Infectious Disease Diagnostic Market Top Key Players, Industry Analysis And Forecast By 2027 | Abbott Laboratories, F. Hoffmann-La Roche Ltd, bioMérieu- SA

Monday, 25 October 2021, 14:05:44
A comprehensive overview of the Infectious Disease Diagnostic market is recently added by UnivDatos Market Insights to its humongous database. The Infectious Disease Diagnostic market report has been aggregated by collecting informative data of various dynamics such as market drivers,
— OpenPR

Morgan Stanley Raises Abbott Laboratories (NYSE:ABT) Price Target to $146.00

Monday, 25 October 2021, 09:06:41
Abbott Laboratories (NYSE:ABT) had its target price boosted by Morgan Stanley from $136.00 to $146.00 in a report released on Thursday morning, The Fly reports. Morgan Stanley currently has an overweight rating on the healthcare product makers stock. Several other analysts have also recently weighed in on the stock. Credit Suisse Group raised their price []
— Dakota Financial News

Abbott Laboratories (ABT) Market Perform Rating Reaffirmed at SVB Leerink

Monday, 25 October 2021, 09:06:41
SVB Leerink reissued their market perform rating on shares of Abbott Laboratories (NYSE:ABT) in a report issued on Thursday, Analyst Ratings Network reports. The firm currently has a $140.00 price objective on the healthcare product makers stock, up from their previous price objective of $128.00. SVB Leerink also issued estimates for Abbott Laboratories Q4 2021 []
— Dakota Financial News